Eisai Begins Enrolling Phase 2 Study for Narcolepsy Treatment E2086
The dose escalation study will evaluate the efficacy, safety, and tolerability of a novel selective orexin-2 receptor agonist in adults with narcolepsy type 1 and type 2.
Tag: Eisai
All
Latest
All
Latest
The Unmet Need for New Insomnia Drugs
While DORAs offer a superior safety profile compared to Z-drugs, they fall short in terms of efficacy, leaving an unmet need for additional drug therapies with a superior efficacy and safety profile.
All
LatestSorry, No Posts Found
FDA Approves Orexin Receptor Antagonist for Insomnia
The US Food and Drug Administration (FDA) has approved the new drug application for Eisai Co...
Read MoreEisai Inc Announces US Approval for Insomnia Drug
Japan-based drugmaker Eisai Co’s US subsidiary announced on Sunday that it had received approval from the US Food and Drug Administration for its insomnia treatment in adult patients. The agency approved the drug, Dayvigo,...
Read More
Are You Missing the Outcomes that Matter to Your Insomnia Patients?
A survey by pharmaceutical company Eisai Inc explored the impact of insomnia or sleeping...
Read MoreEisai Buys Out Purdue’s Rights to Investigational Sleep-wake Regulation Agent
Eisai Inc will buy out Purdue LP’s rights to the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple...
Read More